Induction Therapy With Oral Tacrolimus Provides Long‐Term Benefit in Thiopurine‐Naïve Refractory Ulcerative Colitis Patients Despite Low Serum Albumin Levels
Tacrolimus could have an irreplaceable role in the era of biologic therapies, especially for refractory UC patients with thiopurine-naïve and low serum albumin levels.
Authors
- Hiroyuki Okada (ORCID: https://orcid.org/0000-0003-2814-7146)
- Junki Toyosawa (ORCID: https://orcid.org/0000-0002-4640-6730)
- Toshihiro Inokuchi
- Masahiro Takahara (ORCID: https://orcid.org/0000-0002-4601-6644)
- Setsuro Hiraoka
- Motoyuki Otsuka (ORCID: https://orcid.org/0000-0003-2869-2881)
- Yuki Aoyama (ORCID: https://orcid.org/0000-0002-4658-174X)
- Hideaki Kinugasa (ORCID: https://orcid.org/0000-0003-4887-1609)
- Yasushi Yamasaki (ORCID: https://orcid.org/0000-0002-2992-9863)
- Shoko Igawa
Institutions
- Okayama University (JP)
Publication Details
- Journal
- JGH Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/jgh3.70139
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science